Core Viewpoint - Acurx Pharmaceuticals is preparing to discuss its Q2 2025 financial results and is advancing its lead antibiotic candidate, ibezapolstat, towards international Phase 3 clinical trials for treating C. difficile Infection (CDI) [1][4]. Company Overview - Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [5]. - The company's lead product candidate, ibezapolstat, is designed to treat CDI and is ready for Phase 3 trials, with plans to initiate international clinical trials next year, pending financing [5]. Product Details - Ibezapolstat is a novel, orally administered antibiotic that acts as a Gram-Positive Selective Spectrum (GPSS®™) antibacterial, specifically targeting DNA polymerase IIIC to inhibit DNA replication in Gram-positive bacteria [3][5]. - The antibiotic has received positive regulatory guidance from the EMA, supporting its advancement to Phase 3 trials and potential submission for Marketing Authorization Application (MAA) in Europe [4]. Regulatory Status - Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA, which provides incentives for the development of new antibiotics [4]. - The FDA also granted "Fast Track" designation to ibezapolstat for CDI treatment, highlighting the urgent need for new antibiotics in this area [4]. Upcoming Events - Acurx Pharmaceuticals will host a conference call on August 12, 2025, at 8:00 am ET to discuss its financial results and provide a business update [2].

Core Viewpoint - Acurx Pharmaceuticals has entered into a warrant inducement agreement to facilitate the exercise of existing warrants at a significantly reduced price, generating approximately $2.67 million in gross proceeds for the company [1][2]. Group 1: Warrant Inducement Agreement - The company has a warrant inducement agreement with a holder of existing warrants to purchase up to 4,445,435 shares at exercise prices between $3.25 and $3.26 per share, allowing the holder to exercise these warrants at a reduced price of $0.675 per share [1]. - In exchange for exercising the existing warrants, investors will receive 6,223,609 G-1 warrants and 2,667,261 G-2 warrants, totaling 8,890,870 new warrants [1]. - The G-1 and G-2 warrants are both exercisable at $0.425 per share and will expire five years from the issuance date [1]. Group 2: Use of Proceeds - The net proceeds from the warrant exercise are intended for working capital and general corporate purposes [2]. Group 3: Regulatory and Clinical Development - Ibezapolstat, the company's lead antibiotic candidate, is advancing to international Phase 3 clinical trials for treating C. difficile Infection (CDI) and has received FDA designations that may expedite its development [5]. - The antibiotic is part of a new class of drugs targeting Gram-positive bacteria, which includes significant pathogens like MRSA and VRE [6].

Core Viewpoint - Acurx Pharmaceuticals is preparing to discuss its fourth quarter and full year 2024 financial results on March 18, 2025, highlighting its focus on developing a new class of antibiotics for difficult-to-treat bacterial infections [1][2]. Group 1: Company Overview - Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections [4]. - The company's lead antibiotic candidate, Ibezapolstat, is preparing for international Phase 3 clinical trials aimed at treating patients with C. difficile Infection (CDI) [2][3]. - Ibezapolstat is a novel, orally administered antibiotic that selectively targets Gram-positive bacteria while preserving the gut microbiome [2][3]. Group 2: Regulatory and Clinical Development - Acurx has received positive regulatory guidance from the EMA, confirming that its clinical and non-clinical data supports the advancement of the Ibezapolstat Phase 3 program [3]. - The FDA has designated Ibezapolstat as a Qualified Infectious Disease Product (QIDP) and granted it "Fast Track" designation for CDI treatment, indicating the urgency and need for new antibiotics in this area [3]. - The CDC has classified C. difficile as an urgent threat, underscoring the critical need for new treatment options [3]. Group 3: Upcoming Events - Acurx will host a conference call on March 18, 2025, at 8:00 a.m. ET to discuss its financial results and provide a business update [2].